16:16 , Jan 12, 2017 |  BC Week In Review  |  Company News

Clinigen, Cumberland deal

Clinigen granted Cumberland exclusive rights to commercialize Totect dexrazoxane in the U.S. Cumberland plans to launch Totect in the U.S. later this year. The topoisomerase II (TOP2) inhibitor is approved in the U.S. to treat...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Clinigen Group, Norgine, SpePharm deal

Clinigen will acquire from SpePharm AG - a 50/50 JV between Norgine and SpePharm Holding - rights to Savene dexrazoxane in all markets, excluding North and South America, Israel and South Africa. The topoisomerase II...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

Totect regulatory update

Kissei said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Savene dexrazoxane to treat anthracycline extravasation. The topoisomerase II (TOP2) inhibitor is marketed in the U.S. as Totect and in the...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Clinigen Group, Novartis sales and marketing update

Clinigen acquired Cardioxane dexrazoxane from Novartis for $33 million in cash, which will be paid in two tranches. Clinigen said it plans to "revitalize" the product through "new commercialization, marketing and indication strategies," with a...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Norgine, SpePharm deal

The companies created a 50/50 JV, SpePharm AG, to commercialize SpePharm Holding's entire product profile through Norgine's commercial infrastructure. The products include Dantrium dantrolene, a sodium muscle relaxant to treat malignant hyperthermia, and Savene dexrazoxane,...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Apricus Biosciences, Topotarget deal

Apricus acquired Topotarget's Topotarget USA Inc. subsidiary in a stock deal valued at $2 million up front and up to an additional $2 million in stock based on milestones. Apricus gains all North and South...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Multimeric Biotherapeutics, Topotarget deal

Topotarget granted Multimeric exclusive rights to Topotarget's multimeric fusion proteins containing tumor necrosis factor (TNF) superfamily ligands (TNFSFs) for all therapeutic uses. The deal includes CD40 ligand ( CD40LG ; CD40L; CD154 ) and glucocorticoid-induced...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

Kissei Pharmaceutical, SpePharm sales and marketing update

Kissei received rights from SpePharm to develop and commercialize Savene dexrazoxane in Japan. Terms were not disclosed. SpePharm has rights outside North and South America to Savene from Topotarget A/S (CSE:TOPO, Copenhagen, Denmark), which markets...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Totect dexrazoxane regulatory update

EMA's CHMP recommended that dexrazoxane-containing medicines should be restricted to adult patients with advanced or metastatic breast cancer who have already received treatment with anthracyclines doxorubicin and epirubicin and contraindicated in children and adolescents. Last...